ABSTRACT

Objective: To analyze data from children who were previously healthy and presented with post-varicella arterial ischemic stroke upon arrival when admitted to the emergency room, with focus on the clinical/laboratory aspects, and neurocognitive performance after four-year follow-up.

Methods: Seven children presenting with arterial ischemic stroke after varicella were evaluated at pediatric emergency services in the city of São Paulo (SP), Brazil. Ischemic stroke was determined by magnetic resonance imaging/magnetic resonance angiography in a topography compatible with the areas supplied by the middle cerebral or internal carotid arteries. IgG-class antibodies against varicella-zoster virus and varicella-zoster virus DNA by polymerase chain reaction in cerebrospinal fluid were tested. Patients with prothrombotic conditions were excluded. The Pediatric Stroke Outcome Measure was applied upon admission and 4-years after the stroke.

Results: All patients (age range: 1.3 to 4 years) included presented chickenpox 5.1 (±3.5) months before. All patients had analysis of anti-varicella-zoster-virus-IgG in cerebrospinal fluid, but only three (43%) had a positive result. Of the patients 43% had no vascular lesions identified in magnetic resonance angiography. All patients showed improvement in their sequela scores. After 4 years, five patients displayed good evolution in the Pediatric Stroke Outcome Measure, and only one patient presented with a score of 2 in the sensorimotor and cognition areas. No recurrence of arterial ischemic stroke was observed.

Conclusion: We reinforced the non-progressive course of post-varicella arterial ischemic stroke after 4-year follow-up. The presence of varicella-zoster-virus-DNA detected by polymerase chain reaction, and/or intrathecal IgG antibody against varicella zoster virus, and angiopathy location in magnetic resonance angiography were not determining for the diagnosis. Invasive tests, with low sensitivity, should be well considered in the diagnosis of post-varicella arterial ischemic stroke.

Keywords: Stroke; Basal ganglia cerebrovascular disease; Chickenpox; Child

INTRODUCTION

Arteriopathy caused by viral infections is one of the most important mechanisms of arterial ischemic stroke (AIS) in the pediatric population. Several viruses were previously associated with AIS, such as the varicella-zoster virus (VZV). This is a DNA virus, like the herpes virus, which is able to remain latent in neuronal cells for months after primary infection. Therefore some complications, such as transient cerebral arteriopathy (TCA), may occur up to one year after varicella. Transient cerebral arteriopathy affects the middle cerebral artery (MCA) or...
the internal carotid artery (ICA), manifesting in the basal ganglia of children with symptoms of AIS. Post-varicella AIS, although rare, accounts for approximately 30% of all AIS in children.

To date, there is conflicting evidence regarding the identification of antibodies against VZV, or VZV DNA in cerebrospinal fluid for diagnosis of post-varicella AIS in children.

OBJECTIVE

To analyze data from children who were previously healthy and presented with post-varicella arterial ischemic stroke to emergency room, and focused on the clinical/laboratory aspects and neurocognitive performance after 4-year follow-up.

METHODS

This study reported a series of seven cases of patients admitted to the emergency room with post-varicella AIS and longitudinal follow-up. We evaluated charts of these patients from five different hospitals (Instituto da Criança, Hospital Israelita Albert Einstein, Hospital Santa Catarina, Hospital Infantil Darcy Vargas and Hospital São Camilo) in the city of São Paulo (SP), Brazil, from December 2013 to December 2017. This study was approved by the local Ethics Committee of Hospital das Clínicas of the Faculdade de Medicina of the Universidade de São Paulo (USP), CAAE: 43629315.2.1001.0068, protocol 1.036.344, and Hospital Israelita Albert Einstein (HIAE), CAAE: 43629315.2.3002.0071, protocol 1.343.515.

The inclusion criteria were chickenpox in the past 12 months, referred by parents or guardians, AIS determined by clinical examination and magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA) in a topography compatible with the areas of the MCA or ICA, cerebrospinal fluid sample collected and analyzed, and aged under 18 years. A radiologist reviewed each MRI scan to confirm the presence of AIS. Magnetic resonance imaging and MRA were performed within 24 to 72 hours after the initial visit. All participating hospitals had 1.5 Tesla MRI scanners. Individuals who presented with other risk factors for stroke, such as prothrombotic conditions, cardiopathies, trauma or other cerebral arteriopathies were excluded. Laboratory tests were used to rule out prothrombotic conditions, and two-dimensional Doppler echocardiography was performed to rule out cardiopathies or cervical arterial diseases.

Results from the ELISA of cerebrospinal fluid to detect immunoglobulin G (IgG) antibodies against VZV, and polymerase chain reaction (VZV-DNA-PCR) to detect VZV virus DNA were collected up to 10 days after the onset of AIS in all patients.

Sensorimotor, language and cognitive sequelae were assessed by the Pediatric Stroke Outcome Measure (PSOM) upon admission and 4 years after AIS. Patients were evaluated by physical therapy, speech therapy, and psychology services for specific follow-up, after hospital discharge.

RESULTS

Seven children were included in this study; five of them (71.4%) were male. The median age at stroke was 3.8 years (range: 1.3 to 4), and the mean period between the clinical presentation of AIS and the episode of chickenpox was 5.1 (± 3.5) months.

Table 1 includes a list of demographic parameters, clinical presentations, cerebrospinal fluid results (including IgG antibodies against VZV, and VZV-DNA-PCR), treatments received, and progression. All patients had an analysis of IgG against VZV in cerebrospinal fluid, but only 3 (43%) of them had a positive result.

All patients were initially evaluated by computed tomography, and no signs of mineralizing angiopathy could be found. Figure 1 shows the brain MRI from each of the seven patients. Table 2 shows the description of MR images.

Four patients presented with unilateral vascular lesions in the MCA and/or ICA, while the MRI from three patients were normal. In five children, MRA was repeated after two to eight months to exclude progressive arteriopathy.

Table 3 shows the PSOM results of patients during treatment and 4 years later. After 4 years, four patients had a good progression, and scored zero on the PSOM. One patient had a score of 0.5, which is also considered good. Two patients evolved with scores greater than or equal to 1, corresponding to a moderate deficit with slowness of function. These patients had a greater degree of sensorimotor sequelae and were supported by neurology/psychology and physical therapy groups. One of these two patients presented with a score of 2 in the sensorimotor and cognition areas after 4 years. No recurrence of AIS was observed during the 4-year follow-up.
| Case | Age (years) | Sex | Months after onset of chickenpox | Varicella vaccine | Clinical presentation | CSF analysis | EEG | CSF VZV PCR-DNA | CSF Anti-VZV IgG | Angiopathy-location | Treatment | Evolution |
|------|-------------|-----|---------------------------------|------------------|----------------------|--------------|-----|-----------------|-----------------|-------------------|------------|-----------|
| 1    | 2           | Male| 2                               | No               | Complete and disproportionate right hemiparesis with aphasia since the day before. Strength deficit improved within 72 hours and aphasia within 24 hours. | 2 leukocytes/mm³, protein level and glucose level were normal | Normal | -               | -               | Normal            | ASA        | No deficit |
| 2    | 4           | Female| 4                               | 1 dose           | Disproportionate right hemiparesis and left facial paralysis. The deficit showed progressive improvement, with complete recovery within 7 days. Left hemiparesis episodes within an interval of 2 days. First episode showed complete reversal. Second episode was accompanied by focal convulsive seizures, which resolved spontaneously. He showed no deficits after 10 days and no new episodes of AIS | 10 leukocytes/mm³, with 71% lymphocytes, 25% monocytes, 4% macrophages. Proteins: 0.10g/L. Glucose: 40mg/dL | Normal | -               | +               | Normal            | ASA, acyclovir | No deficit |
| 3    | 4           | Male | 1                               | No               | 2 left hemiparesis episodes within an interval of 2 days. First episode showed complete reversal. Second episode was accompanied by focal convulsive seizures, which resolved spontaneously. He showed no deficits after 10 days and no new episodes of AIS | 5 leukocytes/mm³; proteins: 0.18g/L and glucose: 40mg/dL | Normal | NR              | +               | Normal            | ASA        | No deficit |
| 4    | 4           | Female| 10                              | No              | Complete and disproportionate right hemiparesis, with aphasia that improved after 6 days. No new episodes of AIS or neurocognitive sequel | 4 leukocytes/mm³; proteins: 0.12g/L and glucose: 52mg/dL | Normal | -               | -               | MCA (M1, M2)      | ASA        | No deficit |
| 5    | 1.3         | Male | 5                               | No              | Complete and proportionate hemiparesis with progressive improvement of the motor deficit within 5 days, without new episodes of AIS | 2 leukocytes/mm³; proteins: 0.2g/L and glucose: 42mg/dL | Normal | +               | -               | Distal ICA, A1, MCA (M1) | ASA, acyclovir, corticosteroids | Mild hemiparesis |
| 6    | 3.8         | Male | 4                               | No              | Gradual hemiparesis over a period of 2 days. Evolved with dysarthria and aphasia that resolved 3 days later | 5 leukocytes/mm³; proteins: 0.10g/L and glucose: 56mg/dL | Normal | NR              | +               | Distal ICA, MCA (M1) | ASA        | Mild hemiparesis |
| 7    | 2           | Male | 1                               | No              | Complete and proportionate right hemiplegia, associated with aphasia that improved partially after 10 days. He suffered focal convulsive seizures that evolved with generalization 36 hours after the onset of aphasia, which resolved with the use of phenytoin | 25 leukocytes/mm³ with 65% lymphocytes, 25% monocytes; proteins: 0.43g/L and glucose: 56mg/dL | 5 months later: disorganized background activity on the left hemisphere. Epileptiform activity projecting to the bilateral central and middle regions, with predominance to the left | -               | -               | MCA (M1, M2, M3) | ASA, acyclovir | Epilepsy, hemiparesis |

CSF: cerebrospinal fluid; EEG: electroencephalogram; VZV: varicella-zoster virus; PCR-DNA: Polymerase Chain Reaction- Deoxyribonucleic acid; AIS: arterial ischemic stroke; ASA: acetylsalicylic acid; NR: not related; MCA: middle cerebral artery; ICA: internal carotid artery.
Table 2. Description of the brain magnetic resonance images from each of the seven patients

| Patient | Description |
|---------|-------------|
| Patient-1 | Acute infarction hyperintensity on axial diffusion-weighted image in the left caudate nucleus (A). Magnetic resonance angiography is normal (B) |
| Patient-2 | Acute infarction hyperintensity on axial diffusion-weighted image in the basal ganglia on the right (A). Magnetic resonance angiography is normal (B) |
| Patient-3 | Infarction hyperintensity on axial FLAIR image (A) in the right caudate nucleus. Magnetic resonance angiography is normal (B) |
| Patient-4 | Infarction hyperintensity on axial FLAIR image (A) involving the periventricular white matter to the left. Magnetic resonance angiography (B) shows mild stenosis in the distal portion of the ipsilateral M1 segment |
| Patient-5 | Acute infarction hyperintensity on axial diffusion-weighted image in the basal ganglia to the left (A). Magnetic resonance angiography (B) shows a severe stenosis in the top of the corresponding ICA, extending to the proximal segments of anterior (A1) and middle (M1) cerebral arteries |
| Patient-6 | Chronic infarction hyperintensity on axial T2-weighted image (A) in the basal ganglia to the left; there is compensatory enlargement of the adjacent lateral ventricle and some cavities. Notice also volumetric changes involving almost the entire middle cerebral artery territory, characterized by enlarged sulci. Magnetic resonance angiography (B) shows a severe stenosis in the top of the corresponding ICA, extending to the M1 segment. There is poor characterization of the distal ramifications of this middle cerebral artery |
| Patient-7 | Axial postcontrast T1-weighted image (A) depicts a subacute infarction involving almost the entire territory supplied by the middle cerebral artery. Magnetic resonance angiography (B) shows a severe stenosis in the top of the corresponding ICA, extending to the M1 segment, suggesting the possibility of occlusion / subocclusion of these vessels |

ICA: internal carotid artery.

Figure 1. The brain magnetic resonance images from each of the seven patients with post-varicella arterial ischemic stroke
DISCUSSION

In this study we found the presence of viral DNA and/or intrathecal IgG antibodies against VZV, and angiopathy location in MRA, were not determining for diagnosis of post-varicella AIS. Our study adds to previous literature by describing sensorimotor, language and cognitive sequelae evaluated by the PSOM, in a 4-year follow-up after AIS. Therefore, the need of invasive and low-sensitivity tests should be well considered in the diagnosis of post-varicella AIS.

Only five previous studies included at least four children each, with confirmed radiological imaging characteristic of ischemia in the territories of the MCA or ICA after an episode of varicella (Table 4). (2-6)

Of these, only two (2,6) analyzed the cerebrospinal fluid to look for IgG antibodies against VZV; only five of ten children tested had a positive result for IgG antibodies against VZV. In our study, all patients had an analysis of IgG antibodies against VZV in cerebrospinal fluid and only three (43%) of them had a positive result. Some authors have suggested that, in location where there is universal varicella immunization, tests for IgG antibodies against VZV should be more sensitive than commercial VZV ELISA, (6) which could help explain our anti-VZV IgG detection rates slightly lower than found in previous studies (43% versus 50%). However, given the small sample size, this difference could be explained by variance in the prevalence estimate, and further studies with larger samples are required to clarify this issue. Regarding varicella immunization, there is no association between AIS and live attenuated VZV of varicella vaccine, which has been recommended since 1996. Donahue et al. (9) assessed 3.2 million children, and 1.14 million of them received varicella vaccine in the United States. The authors found varicella vaccine presented no association with increased risk of AIS. In our study, only one patient received one dose of VZV vaccine, probably because in Brazil it was included in the public immunization program only in 2013.

In our study, all children tested had negative results for VZV-DNA-PCR. Helmut et al. (6) identified previously healthy children with AIS, who had a recent history of varicella infection prior to the neurological condition. Nine out of 13 individuals tested had positive results for cerebrospinal fluid-VZV-DNA-PCR. Miravet et al. (10) reported results similar to ours, evaluating children with and without comorbidities. These conflicting findings could be the result of the small sample sizes included; nonetheless, the absence of anti-VZV antibodies in the cerebrospinal fluid does not rule out the diagnosis in children who meet the criteria for post-varicella AIS. (1,6,11)

The main limitation of the present study was the fact it is a series of cases based on data collection from medical records. However, there are only two reports that included more than seven patients with post-varicella AIS, confirmed by MRI and MRA.

Our study reinforces the importance of assessing the approach to diagnose post-varicella AIS, which considers the clinical presentation, history of varicella, neuroimaging findings and, possibly, anti-VZV antibodies in the cerebrospinal fluid. It should also be noted that MRA was unable to rule out the diagnosis, since we observed three patients whose arterial lesions could not be located by MRA, a finding that had been described previously. (6) Other diagnostic techniques, such as conventional arteriography, might be more accurate, but are probably very invasive for routine practice.

Our study highlights the nonprogressive character of post-varicella arteriopathy by the PSOM, in the 4-year follow-up. It has been used to better determine the degree of neurological impairment following AIS over time, since the brain of children is still developing, unlike of adults. (7) After 4 years, the sensorimotor sequelae were more often observed than cognitive and language ones, which reflects the fact post-varicella AIS is mainly subcortical. Additionally, none of our patients

### Table 3. Assessment of sensorimotor, language or cognitive sequelae using the Pediatric Stroke Outcome Measure

| Cases | Language production at AIS time/2018 | Right sensorimotor at AIS time/2018 | Left sensorimotor at AIS time/2018 | Comprehension at AIS time/2018 | Cognition at AIS time/2018 | Score at the time of AIS onset | Final score in 2018 |
|-------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------|--------------------------|-------------------------------|---------------------|
| 1     | 0/0                                 | 1.0/0                               | 0/0                                 | 0/0                           | 0/0                      | 1.0                           | 0                   |
| 2     | 0/0                                 | 0/0                                 | 1.0/0                               | 0/0                           | 0/0                      | 1.0                           | 0                   |
| 3     | 0/0                                 | 1/0.5                               | 0/0                                 | 0/0                           | 0/0                      | 1.0                           | 0                   |
| 4     | 0/0                                 | 1.0/0                               | 0/0                                 | 0/0                           | 0/0                      | 1.0                           | 0                   |
| 5     | 0.5/0                               | 1.0/0.5                             | 0/0                                 | 0/0                           | 0/0                      | 1.5                           | 0.5                 |
| 6     | 2.0/0                               | 2.0/0.5                             | 0/0                                 | 0/0                           | 0.5/0.5                  | 4.5                           | 1.0                 |
| 7     | 2.0/0                               | 2.0/1.0                             | 0/0                                 | 1.0                           | 1.0/1.0                  | 6.0                           | 2.0                 |

0: no deficit; 0.5: minimal deficit without functional consequence; 1: moderate deficit with slowing of function; 2: severe deficit with missing function. AIS: arterial ischemic stroke.
### Table 4. Reports of series of cases (four or more children) evaluating children with post-varicella arterial ischemic, confirmed by magnetic resonance imaging and magnetic resonance angiography

| Authors               | Age  | Months after varicella | PCR-cerebrospinal fluid | Anti-VZV IgG-cerebrospinal fluid | Sex   | Angiopathy or localization | Treatment                   |
|-----------------------|------|------------------------|--------------------------|----------------------------------|-------|-----------------------------|------------------------------|
| Bartolini et al. (2)  | 3.6  | 0.5                    | NR                       | NR                               | Male  | MCA                         | ASA                          |
|                       | 2.2  | 1                      | NR                       | NR                               | Male  | MCA (M1-M2)                 | ASA, heparin, antibiotics    |
|                       | 4.2  | 7                      | NR                       | NR                               | Female| Bilateral A1, left M1       | ASA, valproic acid           |
|                       | 3    | 3                      | +                        | NR                               | Male  | dICA, ACA, MCA              | ASA, acyclovir               |
|                       | 2    | 2                      | -                        | NR                               | Male  | dICA, ACA (M1-M3), MCA      | ASA                          |
| Reis et al. (3)       | 22   | 10                     | NR                       | NR                               | Male  | MCA                         | ASA, enoxaparin              |
|                       | 26   | 10                     | NR                       | NR                               | Female| MCA                         | ASA                          |
|                       | 4.5  | 1                      | NR                       | Female                           | MCA (M1) | ASA                        | ASA                          |
|                       | 10   | 2                      | NR                       | Female                           | MCA (M1) | ASA                        | ASA                          |
| Dunkhase-Heinl et al. (4) | 22 months | 1         | -                       | -                               | Female| MCA (M1) | Acyclovir, prednisone       |
|                       | 15   | 6                      | +                       | +                               | Male  | MCA (M1) | Acyclovir, prednisone       |
|                       | 18   | 5                      | +                       | +                               | Male  | MCA (M1) | Acyclovir, prednisone       |
|                       | 13   | 1.5                    | +                       | -                               | Female| ICA, MCA (M1) | Acyclovir, prednisone       |
|                       | 2    | 6                      | NR                       | NR                               | Male  | ICA                         | NR                           |
|                       | 3.5  | 3                      | NR                       | NR                               | Female| MCA                         | NR                           |
|                       | 5    | 4                      | NR                       | Female                           | MCA, ICA/ACA | NR                     | NR                           |
|                       | 3    | 4                      | -                       | NR                               | Male  | MCA                         | NR                           |
|                       | 8    | 6                      | -                       | NR                               | Female| MCA, ICA                    | NR                           |
|                       | 3    | 2                      | NR                       | NR                               | Male  | NR                         | NR                           |
| Science et al. (5)    | 3.5  | 3                      | _                       | NR                               | Male  | NR                         | NR                           |
|                       | 10   | 0.5                    | NR                       | Female                           | MCA   | NR                         | NR                           |
|                       | 11.5 | 6                      | _                       | NR                               | Female| MCA                         | NR                           |
|                       | 9    | 1                      | NR                       | NR                               | Male  | MCA                         | NR                           |
| Helmuth et al. (6)    | 2    | 3                      | NR                       | NR                               | Male  | ACA                         | Acyclovir, methylprednisolone, ASA, Antibiotics |
|                       | 6    | 1                      | +                       | -                               | Female| MCA (M1) | NR                           |
|                       | 2    | 2                      | +                       | NR                               | Female| Normal                     | NR                           |
|                       | 1    | 1                      | +                       | -                               | Female| MCA, ICA                  | NR                           |
|                       | 4    | 8                      | +                       | +                               | Male  | Normal                     | NR                           |
|                       | 4    | 8                      | +                       | NR                               | Male  | MCA (M2)                  | NR                           |
|                       | 5    | 6                      | +                       | +                               | Male  | ICA                       | NR                           |
|                       | 5    | 5                      | +                       | Male                             | Basilar | NR                     | NR                           |
|                       | 5    | 8                      | +                       | NR                               | Male  | MCA, ACA, ICA            | NR                           |
|                       | 5    | 4                      | +                       | -                               | Male  | MCA, ACA, ICA            | NR                           |

PCR: polymerase chain reaction; IgG: immunoglobulin G; VZV: varicella-zoster virus; MCA: middle cerebral artery; ASA: acetylsalicylic acid; dICA: distal internal carotid artery; ACA: anterior cerebral artery; NR: not related; ICA: internal carotid artery.

presented with new ischemic or hemorrhagic episodes, reinforcing its monophasic course.

Rehabilitation therapy with neuropsychology, physical therapy and speech therapy may improve the outcomes of post-stroke patients, but these therapies have to be more structured in pediatrics. Regarding treatment, all patients received ASA, and two patients in whom intrathecal antibodies were identified received acyclovir. Treatment with acyclovir may be justified by the finding of VZV DNA in the arteries of a child, who died due to post-varicella AIS. Only one patient in this series received corticosteroids. Patients who were not treated with antivirals or corticosteroids showed no higher risk of neurological impairment than those who were; similar results were found by Bartolini et al.\(^2\)

**CONCLUSION**

In this study, we reinforced the nonprogressive course of post-varicella arterial ischemic stroke after 4 years of follow-up. The presence of viral DNA and/or intrathecal IgG antibodies against varicella-zoster virus is an indication for treatment with acyclovir, while corticosteroids are not indicated.
Post-varicella arterial ischemic stroke in children and neurocognitive performance

virus, and angiopathy location in magnetic resonance angiography, were not determining for diagnosis of post-varicella arterial ischemic stroke.

In addition, the necessity of invasive and low-sensitivity tests should be well considered in the diagnosis of post-varicella arterial ischemic stroke.

AUTHORS’ CONTRIBUTION
Regina Maria Rodrigues, Sylvia Costa Lima Farhat and Cláudio Schvartsman: designed the study, analyzed the data, wrote the article and revised the final version.

Tania Miyuki Shimoda Sakano, Paulo Scatulin Gerritsen Plaggert, Regina Maria Rodrigues, Erasmo Barbante Casella and José Albino da Paz: acquired the data, wrote the manuscript and revised the final version.

Leandro Tavares Lucato: performed the image report.

AUTHORS’ INFORMATION
Rodrigues RM: http://orcid.org/0000-0002-6284-1054
Farhat SC: http://orcid.org/0000-0003-4036-5226
Lucato LT: http://orcid.org/0000-0001-9181-5245
Sakano TM: http://orcid.org/0000-0003-4803-5272
Plaggert PG: http://orcid.org/0000-0001-5830-9664
Casella EB: http://orcid.org/0000-0003-0834-9664
Paz JA: http://orcid.org/0000-0003-4977-099X
Schvartsman C: http://orcid.org/0000-0001-5695-9331

REFERENCES
1. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009;8(8):731-40. Review.
2. Bartolini L, Gentilomo C, Sartori S, Calderone M, Simioni P, Laverda AM. Varicella and stroke in children: good outcome without steroids. Clin Appl Thromb Hemost. 2011;17(6):E127-30.
3. Reis AF, Pais P, Monteiro JP. Chickenpox and stroke in children: case studies and literature review. Acta Paediatr. 2014;103(4):e176-80. Review.
4. Dunkhase-Heinl U, Stausbal-Gran B, Christensen J, Ostergaard JR. Post-varicella angiopathy: a series of 4 patients with focus on virologic and neuroimaging findings. Pediatr Neurol. 2014;50(6):581-5.
5. Science M, MacGregor D, Richardson SE, Mahant S, Tran D, Bitnun A. Central nervous system complications of varicella-zoster virus. J Pediatr. 2014;165(4):779-85.
6. Helmuth IG, Melbak K, Uldall PV, Poulsen A. Post-varicella arterial ischemic stroke in Denmark 2010 to 2016. Pediatr Neurol. 2018;80:42-50.
7. Kitchen L, Westmacott R, Frields S, MacGregor D, Curtis R, Allen A, et al. The pediatric stroke outcome measure: a validation and reliability study. Stroke. 2012;43(6):1602-8.
8. Grose C. Biological plausibility of a link between arterial ischemic stroke and infection with varicella-zoster virus or herpes simplex virus. Circulation. 2016;133(8):695-7.
9. Donahue JG, Kieke BA, Yih WK, Berger NR, McCauley JS, Baggs J, Zangwill KM, Baxter R, Eriksen EM, Hambidge SJ, Klein NP, Lewis EM, Marcy SM, Naleway AL, Nordin JD, Ray P, Belongia EA; Vaccine Safety DataLink Team. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009;123(2):e228-34.
10. Miravitl E, Danchevajitr N, Basu H, Saunders DE, Ganesan V. Clinical and radiological features of childhood cerebral infarction following varicella zoster virus infection. Dev Med Child Neurol. 2007;49(6):417-22. Review.
11. Mallick AA, Ganesan V, Kirkham FJ, Fallon P, Hedderly T, McShane T, et al. Outcome and recurrence 1 year after pediatric arterial ischemic stroke in a population-based cohort. Ann Neurol. 2016;79(5):784-93.